- Product
- H. pylori with 50% prevalence requires active examination/tx
- by jung, sae-im Aug 7, 2022 11:29pm
- Helicobacter pylori is a bacteria that causes digestive diseases such as acute gastritis, chronic gastritis, gastric ulcer, duodenal ulcer, gastric lymphoma, and gastric cancer, and is defined by the World Health Organization as a first-class carcinogen. As half of the nation's population is evaluated as Helicobacter infections, the importance o
- Product
- Nearly 100,000 COVID-19 confirmed cases
- by Kim JiEun Jul 28, 2022 05:54am
- Society has no guidelines despite the spread of the disease. As COVID-19 spreads again, face-to-face administration at pharmacies is also increasing significantly. Individual pharmacies are trying to quarantine, but confusion is also detected as it goes against social sentiment. On the 26th, the Central Disease Control Headquarters of the Kor
- Product
- Medical institutions earned ₩7 trillion with COVID-19
- by Kang, Shin-Kook Jul 27, 2022 05:50am
- A whole &8361;7.1028 trillion was spent on medical fees for COVID-19-related matters over the past two and a half years since the pandemic first hit Korea. The medical staff, acclaimed for their efforts in the pandemic, have also earned much for their incredible amount of hard work. In the same period, pharmacies have only earned around &83
- Product
- MOHW meets Doctornow to listen to platform guidelines
- by Kim JiEun Jul 27, 2022 05:49am
- The timing of the announcement of the guidelines for the non-face-to-face treatment brokerage platform announced by the government is later than expected. In addition to the opinions of the medical and pharmaceutical sectors, the government's intention to reflect some of the opinions of platform companies is read. It has been confirmed that t
- Product
- Sell Saxenda directly after non-face-to-face treatment?
- by Jung, Heung-Jun Jul 10, 2022 03:31pm
- Can hospitals sell Saxenda, known as diet injections, directly to patients after non-face-to-face treatment? It is an expensive drug worth more than 100,000 won per unit and there is a high demand for purchase, so it is not prescribed for outpatients. The problem is that some hospitals sell and deliver directly to patients even in non-face-to
- Product
- “Need to raise awareness and seek early diagnosis of Sjogre
- by Eo, Yun-Ho Jul 1, 2022 05:49am
- “We can fully provide the standard of care at local rheumatoid clinics. Have trust and visit a local clinic near you.” If you are experiencing symptoms such as dry mouth, eyes, nose and mucous membrane, skin, or indigestion without underlying diseases or other medication histories for over 3 months but haven’t found its cause, it can b
- Product
- Approval of OTC teleconference bending machine project
- by Kang, Shin-Kook Jun 23, 2022 05:49am
- OTC teleconference bending machine issue, which has been on hold for 10 years, has secured a bridgehead for entering the market under the new government deregulation stance. The Ministry of Science and ICT held an ICT regulatory sandbox review committee on the 20th and approved the OTC teleconference bending machine based on the MOHW's co
- Product
- Prescription of oral COVID-19 drugs drop to 1,800 last week
- by Kang, Shin-Kook Jun 13, 2022 05:54am
- Prescriptions of the oral COVID-19 treatments Paxlovid and Lagevrio have been rapidly decreasing in line with the decrease of confirmed COVID-19 cases in Korea. On the 10th, the Korea Disease Control and Prevention Agency announced that it had prescribed Paxlovid and Lagevrio to 1,800 patients during the past week. From 6:30 p.m. on
- Product
- The supply of Tylenol suspension has been postponed again
- by Kim JiEun May 25, 2022 05:47am
- The sale of children's Tylenol suspension will be extended further. The supplier originally promised to supply it in June, but it seems that it will not be available until August, two months later. Johnson & Johnson Korea recently sent an official letter to drug distributors on the "Delay Notice on the Supply Schedule of Children's Tylenol Suspe
- Product
- Unsure efficacy of Alzheimer's drug aducanumab
- by Choi-sun May 10, 2022 06:07am
- The Korean Dementia Association has reviewed the clinical potential of aducanumab (Aduhelm), the first new drug for Alzheimer's disease to be introduced to the field in 18 years. With the efficacy of the drug under constant debate, and being barely approved for its effect in reducing surrogate biomarkers such as amyloid reduction in Korea and
